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Bayesian methods for voriconazole therapeutic drug monitoring (TDM) have been reported previously, but there are only sparse
reports comparing the accuracy and precision of predictions of publishedmodels. Furthermore, the comparative accuracy of
linear, mixed linear and nonlinear, or entirely nonlinear models may be of high clinical relevance. In this study, models were
coded into individually designed optimum dosing strategies (ID-ODS) with voriconazole concentration data analyzed using in-
verse Bayesian modeling. The data used were from two independent data sets, patients with proven or suspected invasive fungal
infections (n 57) and hematopoietic stem cell transplant recipients (n 10). Observed voriconazole concentrations were pre-
dicted whereby for each concentration value, the data available to that point were used to predict that value. The mean predic-
tion error (ME) andmean squared prediction error (MSE) and their 95% confidence intervals (95% CI) were calculated to mea-
sure absolute bias and precision, whileME andMSE and their 95% CI were used to measure relative bias and precision,
respectively. A total of 519 voriconazole concentrations were analyzed using three models. MEs (95% CI) were 0.09 (0.02, 0.22),
0.23 (0.04, 0.42), and 0.35 (0.16 to 0.54) while the MSEs (95% CI) were 2.1 (1.03, 3.17), 4.98 (0.90, 9.06), and 4.97 (0.54 to 10.48)
for the linear, mixed, and nonlinear models, respectively. In conclusion, while simulations with the linear model were found to
be slightly more accurate and similarly precise, the small difference in accuracy is likely negligible from the clinical point of view,
making all three approaches appropriate for use in a voriconazole TDM program.
Voriconazole is a triazole antifungal that exhibits broad-spec-trum activity and is a first-line agent for the treatment ofCan-
dida sp. infections (1), invasive aspergillosis (2), and other serious
fungal infections. With increasing numbers of at-risk immuno-
compromised populations, such as those undergoing solid-organ
transplantation or those with HIV infections, the incidence of
invasive mycoses is on the rise (3, 4). Despite the advent of newer
antifungals, Aspergillus sp. and Candida sp. infections have exhib-
ited high mortality rates of 60% and 30%, respectively (5, 6).
Recent published studies of voriconazole have shed light on the
clinical relevance of therapeutic drug monitoring (TDM) for op-
timization of dosing based on voriconazole’s highly variable phar-
macokinetics (PK) and the resultant poor predictability of plasma
concentrations (7, 8). Subtherapeutic concentrations have been
linked to higher failure rates in patients with life-threatening in-
vasive fungal infections, and supratherapeutic concentrations are
associated with neurological and hepatic toxicity (9–19). Vori-
conazole is primarilymetabolized by CYP2C19, which commonly
exhibits genetic polymorphism, leading to variable PK and leaving
certain populations susceptible to decreased metabolism and in-
creased plasma concentrations of voriconazole (20–23). Patients
of Asian descent with polymorphisms in CYP2C19 have up to a
20% incidence of being poormetabolizers while this value is up to
5% for Caucasian and African American individuals (24). Poor
metabolizers can have a PK exposure up to four times higher than
that of homozygous comparators.
Nonlinearity in voriconazole PK relating to saturable clearance
mechanisms has been reported (8), which together with its exten-
sive variability makes dosing profoundly challenging, especially
when higher doses are used. Conversely, several previous studies
have reported adequate results when voriconazole PK is described
by one- and two-compartment linear models such that in one
study (7) the absence of saturable eliminationwas noted evenwith
dosing regimens at larger than approved levels (9, 10, 20). Incor-
porating adaptive feedback in PK models can allow true person-
alization of therapy by the design of dosing regimens that achieve
the desired exposure targets with improved precision based on the
observed concentrations. Bayesian feedback is highly useful for
the extrapolation of the “information” contained within single or
multiple voriconazole concentrations measured at any time dur-
ing the course of therapy. The Bayesian system uses single or mul-
tiple voriconazole concentrations measured at any time during
the course of therapy as patient-specific information to identify
factors that affect different PK parameters in an individual patient
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and therefore drug concentrations. Once identified, PK relation-
ships can be used to enable optimized real-time adjustment of
voriconazole dosing regimens (25). In order to determine the
model(s) best suited for use in a voriconazole TDMprogram sup-
ported by adaptive feedback and Bayesian forecasting, this study
compared the predictive performance of three different voricona-
zole PK models (a linear model, a nonlinear model, and a mixed
linear-nonlinear model) (7, 23, 26).
MATERIALS AND METHODS
Patient selection and data collection. Two separate voriconazole data
sets were used in this analysis. First, a TDM data collection and observa-
tional study was approved by the local hospital and university ethics com-
mittees (Royal Brisbane and Women’s Hospital and The University of
Queensland), with a waiver for informed consent granted because of the
retrospective nature of the study. This first data set included adult patients
who had received voriconazole for prophylaxis or treatment for suspected
or proven fungal infections and who had at least two plasma voriconazole
samples available from routine clinical TDM (samples were taken as peak
and trough samples). Data were collected from December 2009 to July
2012. Demographic data collected included sex, age, and total body
weight. Drug administration and blood sampling histories, including the
route of administration, date, time, and actual dosage given, were also
collected.
Second, a previously published set of voriconazole PK data and dosing
information from 10 hematopoietic stem cell transplant (HSCT) recipi-
ents was also used (27). This patient group all received the FDA-approved
standard regimenof 6mg/kg every 12 h (q12h) intravenously (i.v.) for two
doses followed by 4 mg/kg q12h i.v. for 2 weeks. Plasma concentration-
time data from this study were extracted from the published paper using
WebPlotDigitizer (http://arohatgi.info/WebPlotDigitizer/).
Determination of voriconazole concentrations. For the first data set,
voriconazole plasma samples were precipitated with two-volume equiva-
lents of acetonitrile containing deuterated internal standards. After pro-
tein precipitation, the samples were centrifuged, and the supernatant was
transferred to an autosampler vial. An aliquot of 2l was injected onto an
ultraperformance liquid chromatography tandem mass spectrometry
(UPLC-MS/MS) system operating in positive electrospray ionization
(ESI) mode. Voriconazole samples and the deuterated internal standards
were measured using selected reaction monitoring. The accuracy range
varied from 100 to 102%; intraday precision varied between 2% and 2.9%
while interday precision was between 4% and 4.5%. For the second data
set, themethods used to determine voriconazole concentration have been
published elsewhere (27).
Evaluation of population pharmacokinetic models. The dosing ap-
plication used to predict plasma voriconazole concentrations taking into
account patient demographic and laboratory information for these anal-
yses used individually designed optimum dosing strategies (ID-ODS)
(http://www.optimum-dosing-strategies.org/). ID-ODS is a TDM and
simulation tool powered by the R software (version 2.15.3; Institute for
Statistics and Mathematics [http://www.r-project.org/]) (28–30). Based
on patient demographic information readily available at the bedside, ID-
ODS incorporates Monte Carlo simulation and inverse Bayesian model-
ing (31) into the design of personalized dosing regimens. Voriconazole
concentration-time profiles were simulated using inverse modeling based
on linear, mixed linear and nonlinear, and fully nonlinear one- and two-
compartment i.v. infusion models written in the R language using the
published population pharmacokinetic parameter values and respective
interindividual variabilities. Changes in the estimated PK parameters
were allowed to ensure that changing physiological variables were incor-
porated during the course of therapy.
Bland-Altman plots were constructed to evaluate the agreement be-
tween observed and predicted concentrations using the calculated per-
centage mean differences and their 95% limits of agreement. The 95%
confidence interval (CI) for the percent mean difference was also deter-
mined such that the inclusion of the value of zero in the interval would
indicate the lack of a statistically significant degree of systematic bias be-
tween the observed concentrations and model predictions. Also, it was
expected that approximately 95% of the percent differences between the
observed and predicted values would lie between the percentmean differ-
ence 1.96 standard deviations (SD), called the limits of agreement.
These limits of agreement were then employed to indicate whether there
was any difference inmagnitude between the three competingmethods in
the agreement for the data from the observed and the predicted concen-
trations (32). Prediction errors were evaluated to outline the absolute and
relative biases and precision of the three dose optimization strategies.
Absolute bias and precision were established by calculating mean predic-
tion errors (ME) and mean squared prediction errors (MSE) and their
95% confidence intervals, while relative bias and precision were estab-
lished by calculating the changes in mean prediction errors (ME) and in
mean squared prediction errors (MSE) and their 95% confidence inter-
vals, respectively (33). These measures of bias and precision were identi-
fied by evaluating all predictions at once and at intervals of predictions
based on sequences in the time course of therapy and as new measured
concentrations became available from the first set of plasma concentra-
tions through the fifth set of concentrations. The aim of this approachwas
to identify possible differences in system adaptations to measured con-
centrations and resulting Bayesianmodel predictions. Furthermore,mea-
sures of predictive performance were calculated separately for patients on
dosing regimens greater than the recommended 4mg/kg q12h to compare
the models in the range of dosages where saturable elimination could be
suspected (34). The clinical significance of the results was also evaluated
by calculating the percent agreements between the decisions made for the
need to dose adjust based on the observed versus the predicted concen-
trations. The chosen target trough concentration rangewas 2 to 5mg/liter.
For interpreting the need for dose adaptation, if the trough concentration
was2 mg/liter, the dose was increased, and if the trough concentration
exceeded 5 mg/liter, then the dose was decreased. Dose adjustments were
not required when the predicted or observed trough concentration was
between 2 mg/liter and 5 mg/liter. Confidence intervals for the means of
the error estimates were calculated by a one-sample Student’s t test using
the R software.
Simulation to demonstrate the clinical utility of using the patient-
specificmodels.Weemployed theBayesian inversemodeling approach to
illustrate its potential use for a simulated patient with trough concentra-
tions predicted to be5 mg/liter and at increased risk of concentration-
dependent toxicity. This patient was to receive the standard regimen of 6
mg/kg i.v. q12 h on day 1 and then 4mg/kg i.v. q12h onward.We used the
trough concentration measured before the seventh dose to establish the
patient-specific model, and then we predicted future concentrations after
2weeks of treatment and suggested a revised dosing regimen to potentially
avoid supratherapeutic concentrations.
RESULTS
Patient characteristics and dosing data. TDM data from the two
data sets included 67 adult patients with a total of 519 collected
samples available for analysis. The mean number of concentra-
tions per subject was 7.7. The patient demographic and clinical
characteristics are shown in Table 1. Indications for the use of
voriconazole varied among the patients, with treatment of sus-
pected or proven fungal infections being the most common rea-
son for administration. The doses of i.v. and oral voriconazole
ranged from 200 to 400mg andwere given at intervals of 8 to 12 h,
with seven patients receiving more than 8 mg/kg/day i.v. or orally
following the initial i.v. loading doses (Fig. 1).
Comparative accuracy of observed concentrations with
model-based predictions. Three population PK models were
available to predict voriconazole concentrations for the individual
patients (Fig. 2) using Bayesian methods. Overall, the mean (95%
Comparison of Voriconazole PK Models
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CI) percent difference ranged from 3.57% (2.33%, 9.48%) for
themixed to 7.51% (1.82%, 13.21%) for the fully nonlinear and to
11.74% (6.45%, 17.02%) for the fully linear models, respectively.
The linear model was found to be slightly more in agreement
with the measured concentrations, as evidenced by the narrow-
est range of the 95% limits of agreement (95% CI) of108.33%
(117.47%,99.19%) to 131.81% (122.68%, 140.95%). Plots of
relative percentages for all models are shown in Fig. 3. The predic-
tive performances of these three methods were also compared by
calculating ME, MSE, ME, and MSE. Table 2 describes the
absolute and relative performances of the three approaches in
terms of ME andMSE against the observed concentrations and of
theME andMSE against the method with the leading absolute
performance (the fully linear approach). Compared to the linear
predictor, the mixed model showed a ME (95% CI) of 0.13 mg/
liter (0.01 mg/liter, 0.27 mg/liter), and the nonlinear approach
had a ME (95% CI) of 0.25 mg/liter (0.11 mg/liter, 0.40 mg/
liter). All models were found to be equally precise, as evidenced by
the nonsignificantly different MSE (95% CI) values of 2.88 mg/
liter2 (0.82mg/liter2, 6.59mg/liter2) for themixed approach and
a MSE (95% CI) of 2.86 mg/liter2 (2.30 mg/liter2, 8.03 mg/
liter2) for the nonlinear method.
The accuracy and precision of the predictions for the three
methods against the observed concentrations after the first, sec-
ond, third, fourth, or fifthmeasured set of concentrations became
available for dose optimization are shown inTable 3.We found no
indications of onemodel being particularly superior to the others,
as evidenced by the constant change in the significance and mag-
nitude of ME and MSE values for predictions based on the first
through the fifth sets of concentrations. Similar results showing
the lack of significant differences in predictive performance were
found during analysis of 46 concentrations measured in patients
receiving doses greater than 8 mg/kg/day, as evidenced by the full
set of 95% CIs crossing the value of zero for the ME and MSE
measurements (Table 4). The difference in the predictions from
the studied models in terms of whether a dose adjustment is indi-
cated was established using 356 trough concentration measure-
ments. Dose adjustment decisions predicted by the threemethods
agreed with the decisions determined by the observed concentra-
tions 79.5%, 78.9%, and 78.7% of the time for the linear, mixed,
and nonlinear models, respectively.
Simulation to demonstrate clinical utility of using the pa-
tient-specificmodels.The usefulness of the patient-specificmod-
els for TDM is illustrated in Fig. 4, which represents a patient for
whom the standard voriconazole regimen after time results in a
trough concentration that is higher than the target of5mg/liter.
Adjusting the dose to 3 mg/kg q12h i.v. starting with the seventh
dose would satisfactorily correct the plasma profile and would
achieve trough concentrations in the safe range of 2 to 5 mg/liter.
DISCUSSION
An aim of the published PK models studied here is to predict
voriconazole concentrations from dosing regimens in individual
patients. Indeed, aiming for voriconazole exposures associated
with maximal clinical effects will increase the likelihood of opti-
TABLE 1 Demographics and clinical characteristics of the studied
patients
Characteristic
Value for the groupa
Total study
population (n 67)
Cohort I
(n 57)
Cohort II
(n 10)
Age (yr) 51 (38.7, 60) 52 49
Weight (kg) 77 (64.2, 85.7) 76 82.8
Male (% of subjects) 61 59 70
Hematological/oncological
underlying disease
(% of subjects)
100 100 100
Indication for voriconazole
use (% of subjects)
Treatment of proven or
suspected fungal
infection
17 19 0
Prophylaxis of fungal
infection
44 35 100
Graft versus host diseases 15 18 0
Febrile neutropenia 24 28 0
a Data are presented as medians (interquartile ranges), unless otherwise noted.
FIG 1 Histogram of daily voriconazole doses administered.
Farkas et al.
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mal treatment outcomes, including minimization of the emer-
gence of drug toxicity. The results of this analysis appear to con-
firm the suitability of all three models for accurately and precisely
predicting voriconazole concentrations in a heterogeneous cohort
of patients. We found similar frequencies of dose adjustments
recommended by the linear, mixed, and nonlinear models at
79.5%, 78.9%, and 78.7%, respectively.
The use of standardized voriconazole dosing regimens has
proved to be inadequate at achieving optimal target therapeutic
exposures in various clinical settings (7, 8). In a population PK
and Monte Carlo simulation study, the proportions of patients
(n 64) receiving i.v. and oral voriconazole with concentrations
outside the recommended therapeutic range were 43.3% and
58.5%, respectively (8). Utilizing a priori and a posteriori PK ap-
proaches to dosing can increase the likelihood of achieving opti-
mum PK/pharmacodynamic (PD) targets of voriconazole.
The relationship between voriconazole plasma exposure and
improved clinical outcomes was initially described in a phase II
study of voriconazole for invasive aspergillosis. In this study, a
serum concentration of 0.25 mg/liter was associated with a
higher probability of clinical failure (35). In another study of 34
patients with hematological disease given chemotherapy, all TDM
patients with voriconazole serum concentrations of 2 mg/liter
showed positive response. Two out of six TDMpatients with con-
centrations of2 mg/liter were nonresponders (16). Meanwhile,
in amulticenter study of voriconazole PK and TDM involving 201
patients, 26% of patients with concentrations of 1.7 mg/liter
failed treatment while only 7% of patients with concentrations of
1.7 mg/liter were nonresponders (14). Comparable serum con-
centrations for treatment failure were found in a study by Pascual
et al., where patients with concentrations of 1.5 mg/liter had
85% probability of response (11). A higher target (e.g., 2 mg/
FIG 2 (A) One-compartment model with first-order absorption and linear elimination. (B) Two-compartment model with first-order absorption and mixed
linear and nonlinear (Michaelis-Menten and time-dependent Vmax) elimination. (C) Two-compartment model with first-order absorption and nonlinear
(Michaelis-Menten) elimination.Ka, absorption rate constant; CL, linear clearance; CLnon-lin, nonlinear clearance [Vmax/(Cp	Km), whereVmax is themaximum
elimination rate,Cp is the plasma voriconazole concentration, andKm is theMichaelis-Menten constant];V, volume of distribution of the central compartment;
K12 and K21, transfer rate constants to and from the peripheral compartment, respectively.
FIG 3 Bland-Altman plots of relative differences between predicted (Pred) and observed (Obs) voriconazole concentrations against the mean of predicted and
measured concentrations for the tested models. The biases and 95% limits of agreements are shown as solid and broken lines, respectively.
Comparison of Voriconazole PK Models
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liter) may be warranted if there is disease with a poor prognosis
(e.g., central nervous system [CNS] infection, bulky disease, or
multifocal infection). This target is also supported by a number of
retrospective studies suggesting a relationship between drug ex-
posure and positive results, where the target concentration of2
mg/liter was identified as being associated with improved out-
comes (13–16, 36). Studies completed to evaluate effects of vori-
conazole TDM on patient outcomes have also yielded promising
results. Park et al. compared clinical outcomes in patientswhohad
voriconazole dosages adjusted based on plasma concentrations
with the outcomes in those who received a fixed regimen. In this
study, outcome measures of complete or partial response and a
reduction in rate of drug discontinuation resulting from adverse
side effects in patients undergoing TDM were significantly better
than those in the non-TDM group (18).
The evidence supporting the need for an upper concentration
thresholdwith voriconazole is based ondata of neurotoxic adverse
events (such as hallucinations, confusion, and encephalopathy),
which appear to be associated with a steep exposure-response re-
lationship, as opposed to aweaker exposure-response relationship
with hepatotoxicity (37). While voriconazole toxicity thresholds
of 5 mg/liter have been identified in some studies, the recently
updated 2016 practice guidelines for the diagnosis and manage-
ment of aspergillosis from the Infectious Diseases Society of
America (IDSA) support an upper threshold of5 to 6mg/liter to
minimize toxicity (2).
The present study is highly valuable and establishes that the
currently available published PK models for voriconazole are all
suitable for inclusion in Bayesian forecasting (with or without
adaptive feedback) software. Such an approach is likely to result in
a more rapid achievement of therapeutic voriconazole exposures.
Interestingly, the results of our comparison for the predictive per-
formance of the Bayesianmodels established using TDMdata in a
diverse group of patients showed a numerical advantage for re-
duced bias for the linear model over the two other models. No
significant difference was found in precisionmeasures. The favor-
able, although likely clinically insignificant, performance of the
linear model compared to that of the often cited nonlinear PK
models of voriconazole is perhaps unsurprising for the following
reasons. First, published reports in adult and pediatric patients in
the past appropriately described voriconazole PK with one- or
two-compartment linear models wherein the evaluation of the
structural approaches with nonlinear elimination did not result in
improved prediction of the observed concentrations compared
with that with the linear models (9, 10, 20). Second, we used a
sequential approach to Bayesian modeling, which allowed the PK
parameter values to change during the course of therapy. Prior
analysis using this approach also reported improved predictive
performance for aminoglycosides and vancomycin. That study
hypothesized that the superior predictions were due to the better
adaptation of the models to the patients’ changing physiologic
parameters (38). Third, the dosing regimens and the patient pop-
ulation evaluated in our study were unlikely to represent the ideal
population to show meaningful variability in dose- and metabo-
lism-related differences in saturable metabolism of voriconazole.
Our population consisted of mostly patients of Caucasian descent
for whom the percentage of the population expected to exhibit
nonlinear clearance is equal to or less than 5%. Fourth, the iden-
tification of nonlinear PK of voriconazole is commonly realized in
subjects with dosing regimens that are altered over time, a strategy
that was infrequently applied in our cohort of patients. Moreover,
the nonlinearity in PKhas been previously described at doses of 10
mg/kg/day or higher, a daily dose intensity that was achieved in
only two patients, representing a small portion of the studied pop-
ulation here (34).
Another aspect of the study relevant for the clinical setting is
the rather inconsistent change—as opposed to the clear improve-
ment onemay expect—in themeasures of predictive performance
of the models as the number of observed concentrations included
TABLE 2 Evaluation of the predictive performance of the studied models
Model ME (mg/liter [95% CI])a MSE (mg/liter2 [95% CI])a ME (mg/liter [95% CI])b MSE (mg/liter2 [95% CI])b
Linear 0.09 (0.02–0.22) 2.10 (1.03–3.17)
Mixed 0.23 (0.04–0.42) 4.98 (0.90–9.06) 0.13 (0.00–0.27) 2.88 (0.82–6.59)
Nonlinear 0.35 (0.16–0.54) 4.97 (0.54–10.48) 0.25 (0.11–0.40) 2.86 (2.30–8.03)
a Bias and precision of the models were ranked according to the mean prediction errors (ME) and mean squared prediction errors (MSE), respectively, in relation to the observed
concentrations.
b Bias and precision of the models were ranked according to the ME and MSE, respectively, in relation to the linear model.
TABLE 3 Evaluation of the predictive performance of the studied
models against the observed concentrations after the first, second, third,
fourth, or fifth measured set of concentrations became available for dose
optimization
Concn set
and model
ME (mg/liter
[95% CI])a
MSE (mg/liter2
[95% CI])b
First
Linear 0.32 (0.09–0.73) 2.61 (1.09–4.13)
Mixed 1.13 (0.41–1.86) 9.05 (3.03–15.07)
Nonlinear 0.94 (0.34–1.53) 6.06 (2.09–10.03)
Second
Linear 0.12 (0.63–0.38) 3.60 (0.21–6.99)
Mixed 0.22 (1.03–1.48) 21.69 (15.46–58.86)
Nonlinear 0.72 (0.69–2.14) 28.15 (23.42–79.73)
Third
Linear 0.75 (0.00–1.51) 6.88 (4.42–18.20)
Mixed 0.39 (0.30–1.10) 5.57 (0.73–11.88)
Nonlinear 0.63 (0.00–1.28) 4.92 (0.73–10.58)
Fourth
Linear 0.45 (0.03 to 0.86) 1.52 (0.44–2.16)
Mixed 0.33 (0.21–0.88) 2.42 (0.38–4.47)
Nonlinear 0.13 (0.35–0.62) 1.87 (0.44–3.31)
Fifth
Linear 0.35 (0.95–0.25) 2.56 (0.58–5.72)
Mixed 0.66 (1.35–0.01) 3.57 (0.01–7.12)
Nonlinear 0.37 (0.91–0.16) 2.08 (0.11–4.28)
a ME, mean prediction error.
b MSE, mean squared prediction error.
Farkas et al.
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in the modeling process increased during the course of therapy.
This may be the result of the inherent limitations of our data,
which were derived mostly from therapeutic drug monitoring of
voriconazole trough concentrations, a rather poorly informative
concentration-time point design. The purpose of trough concen-
tration monitoring for voriconazole is mainly to ensure that the
trough measurement is within the therapeutic range and not nec-
essarily to describe the exact pharmacokinetic profile of a specific
patient. Optimal sampling times, a potentially more onerous ap-
proach to the day-to-day care of the patient, that are maximally
informative can be used to more accurately describe individual
voriconazole pharmacokinetics that, when applied, may have the
potential to improve predictions of future concentrations in the
clinical setting (8).
The last limitation of these results may be that our cohort of
patients were subjects with hematological malignancies, exclusive
of the solid-organ transplant population, a groupwhere voricona-
zole pharmacokinetics are likely to be influenced by specific cova-
riates that are distinctive of that subset of the population. There-
fore, extrapolating this study’s results to those patientsmay not be
appropriate (20).
Conclusion. To the best of our knowledge, this is the first pa-
per comparing the predictive performance of the Bayesianmodels
using linear, mixed linear and nonlinear, and fully nonlinear
structural approaches in patients where voriconazole was used for
treatment or prophylaxis of fungal infections. We found the pre-
dictive performance of all models to be sufficient for use in daily
practice and for TDM, and we found that these models tend to
slightly overestimate the observed concentrations, which in some
circumstances could potentially lead to the design of suboptimal
dosing regimens resulting in higher risks of treatment failure but a
lower risk of toxicity in the clinical setting. The observed values of
ME (95% CI) of 0.13 mg/liter (0.01 mg/liter, 0.27 mg/liter) for
the mixed model and the ME (95% CI) of 0.25 mg/liter (0.11
mg/liter, 0.40 mg/liter) for the nonlinear approach compared to
the values with the linear method in our opinion represent a clin-
ically insignificant difference in accuracy, making all three ways
equally adaptable for use in the clinical setting for a TDM pro-
gram.
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